

National Depression Management Leadership Initiative to Improve Clinical Management of Depression Launched

Three national medical specialty groups whose members play the predominant role in caring for patients with major depression have teamed up to improve the quality and availability of treatment for the disorder, which affects an estimated 9 million American adults in a given year. The project involves a novel collaboration among the American Psychiatric Association (APA), the American Academy of Family Physicians (AAFP) and the American College of Physicians (ACP). Aims are to enhance the clinical management of depression by: 1) assessing the clinical utility of a simple quantitative instrument (the nine-item Patient Health Questionnaire – PHQ-9) for identifying and measuring depression severity; and 2) developing and testing office systems and management strategies to optimize monitoring of depression in routine clinical practice.

“As a simple, brief patient-reported depression screening and severity monitoring tool, the PHQ-9 holds significant promise in greatly improving treatment for depression – much like blood pressure monitoring for hypertension or Hemoglobin 1AC tests for diabetes,” according to Darrel A. Regier, M.D., M.P.H., Executive Director of APIRE and Director of the APA Division of Research. *“As a consequence, there’s great interest in this initiative, particularly since*

the PHQ-9 includes a measure to assess suicidality which is increasingly important to document,” notes Regier, who brought about this collaborative effort with the support of the American Psychiatric Foundation (APF).

David Katzelnick, M.D., project Principal Investigator, remarked, *“I am very excited to see the APA, the American Academy of Family Physicians and the American College of Physicians collaborating to improve care for our patients who are depressed. We are hopeful that this initiative will help disseminate advances achieved in depression effectiveness studies to patients treated in clinical practice.”*

The *National Depression Management Leadership Initiative* has enrolled 18 primary care and 20 psychiatric practices (including 12 PRN members), each represented by a “team” consisting of a physician and a non-physician colleague who will work as change agents within their respective practices. Over a 12-month period, these teams will participate in three weekend-long “Learning Sessions” in which they will work together, to learn and refine effective depression management strategies. In the intervening “Action Phases,” participants will introduce and routinize these strategies in their practices.

The first Learning Session took place in Chicago April 8th-10th. Project facilitators, including Katzelnick, Henry Chung, M.D., and Madhukar Trivedi, M.D., (Co-Principal Investigators), and others provided information about evidence-based care for depression, use of the PHQ-9 for monitoring depression severity, patient self-management, suicide monitoring, and other topics that

provided practices with tools to implement change in their practices. The 38 teams engaged in enthusiastic discussions as they developed initial Plan-Do-Study-Act (PDSA) cycles to test simple office systems to improve depression management upon their return to their practices.

At the conclusion of this project, participating practices will take part in disseminating their efforts in depression management to other colleagues and practices nationwide, advancing our knowledge base with respect to dissemination and implementation processes and mechanisms that will enhance uptake of scientifically-based treatments and services in routine clinical care.

This project recently received full funding under a \$1.14 million grant from the American Psychiatric Foundation (APF). APF funding is made possible by unrestricted grants from: AstraZeneca International, Eli Lilly and Company, Lilly Foundation, Forest Laboratories, Inc., Pfizer Inc., Sanofi Aventis, and Wyeth.

On behalf of the full team of project directors, Dr. Regier expressed appreciation to the 38 practices that have taken on a leadership role in testing, implementing, and sharing strategies for incorporating routine use of the PHQ-9 into the variety of service settings they represent. *“Achieving a change in national practice patterns is a formidable task, but we are confident that project participants have the commitment and energy to serve as a nucleus for change that will benefit patients with depression who are seen in practice settings throughout the country,”* he said. To learn more about this new initiative, please contact Farifteh Duffy, Ph.D. at 800-713-7123, or fduffy@psych.org.



PRN 2005 Annual Meeting Events

This year's Annual Meeting takes place in Atlanta, GA from May 21st-26th. The PRN is excited to host several events of interest to both clinicians and researchers.

See page 3 for details.

Access to Psychiatrists in the Public Sector and in Managed Care Plans

Recent findings from the Practice Research Network's 2002 *National Survey of Psychiatric Practice* raise troubling questions about access to psychiatrists by patients with Medicaid and managed private insurance plans. The aim of the analyses was to assess the extent to which psychiatrists are able to accept new patients with different types of insurance and in managed care plans versus non-managed plans.

Overall, 85% of psychiatrists reported accepting new patients. However, psychiatrists' acceptance of new patients was significantly associated with the type of health plan/payment option to which the patient belonged (Fisher exact test, $p < .0001$, Table 1). While most psychiatrists (77%) were accepting patients who were self-pay, less than half were accepting patients who used Medicaid (44%). Sixty-five percent of psychiatrists surveyed were accepting new patients who used unmanaged private insurance, while significantly fewer (53%) accepted new patients from private insurance plans that were managed. Only 48% of psychiatrists reported serving on any managed care panels, with over 25% of those who were on panels not accepting new patients from those panels. Additionally, 63% of psychiatrists accepted new patients who used Medicare, significantly higher than those who accepted patients in both private managed insurance plans and Medicaid.

These data are especially disconcerting given that the majority of individuals receiving treatment for a mental or addictive disorder receive care through Medicaid and other sources of public funding which are expected to be increasingly constrained(1); and the majority of privately insured individuals in the US (70%) are enrolled in private managed plans (2). Further, the psychiatry workforce as a whole is aging, working fewer hours and spending less time in patient care (3). This suggests that the availability of psychiatric resources may continue to decline as the number of psychiatrists and the amount of their time spent in direct patient care continues to be restricted. Clearly, these trends suggest that access to psychiatric care may continue to follow a downward trend.


As psychiatrists are the primary provider of psychopharmacological treatments in the mental health sector, access to psychopharmacologic treatments, which have become increasingly important in the treatment of mental disorders, is of particular concern. Reductions in the number of psychiatrists accepting new patients in an already declining workforce will likely be associated with delays in treatment and a potential decrease in quality of care.

You can read more about these findings in the April 2005 issue of *Psychiatric Services*.

References

1. Mark TL, Coffey RM, Vandivort-Warren R, Harwood HJ, King EC: U.S. spending for mental health and substance abuse treatment, 1991-2001, *Health Aff*;W5:133-142, 2005.
2. Scheffler RM: Managed behavioral health care and supply-side economics. 1998 Carl Taube Lecture; *J Ment Health Policy Econ*; 2:21-28, 1999.
3. Scully JA, Wilk JE: Selected characteristics and data of psychiatrists in the United States 2001-2002; *Acad Psych*; 27: 247-251, 2004.

Figure 1. Rates of Accepting New Patients and Insurance/ Health Plan Type



Source: 2002 PRN National Survey of Psychiatric Practice

APF Barriers to Care Grant Update: *Health Insurance and Managed Care in Psychiatry Study*

The PRN is fielding a study designed to examine the impact of health insurance and managed care in psychiatry and the mental health parity provision in the Federal Employees Health Benefits Program (FEHBP) as compared to the full range of other private and publicly funded insurance programs in the Washington DC metropolitan area. The *Health Insurance and Managed Care in Psychiatry Study* has been the current focus of our *American Psychiatric Foundation (APF) Barriers to Care* grant. The specific goals of the study are to assess how the management and financing of mental health benefits affects treatment provision and access to mental health care. This study is unique in that the American Psychological Association and the National Association of Social Workers are collaborating with us to provide a broader assessment of the impact of health insurance and managed care on treatment access.

APF funding has also been used to develop external grant and contract support for three new studies focusing on improving and addressing barriers to best practices in the treatment of depression and schizophrenia. Two of these proposals received funding and are underway: *Improving Treatment of Depression in Primary Care and Psychiatric Practice Settings* (see story on page 1) and *Development and Effective Dissemination of Quality of Care Measures for Schizophrenia Treatment Guidelines*, which is being funded

continued on page 5

PRN 2005 Annual Meeting Events

This year's Annual Meeting takes place in Atlanta, GA from May 21st - 26th. The PRN is excited to host the following events of interest to both clinicians and researchers. We hope that you will join us!

Psychiatric Management of Treatment-Resistant Schizophrenia

Leading experts will present current empirical and expert consensus data defining the most promising psychopharmacological and psychosocial interventions for treatment-resistant schizophrenia. John S. McIntyre, M.D. and Darrel A. Regier, M.D., M.P.H. will co-chair this forum. This session will feature Dr. Alexander Miller, who will discuss strategies for switching antipsychotics, the effects of combinatory drug treatments, and comment on the most widely used evidence- and expert-consensus based recommendations for the treatment of treatment-resistant schizophrenia. Dr. Jeffrey Lieberman will present relevant findings from the CATIE Trial, an 18 month study which evaluated the effectiveness of various antipsychotic medications. Dr. Peter Weiden will present data which supports the use of CBT in treatment-resistant patients with schizophrenia. Dr. Mark Olfson will present data from a large national sample of psychiatrists characterizing the strategies practicing clinicians currently use to manage treatment-resistant schizophrenia and the reported outcomes of these efforts.

Tuesday, May 24, 2005 from 12:00-1:30 pm in Room A410, Level 4, Georgia World Congress Center.

Child and Adolescent Psychopharmacology

In this Scientific and Clinical Reports Session, the PRN's Farifteh F. Duffy, Ph.D. will discuss the prevalence of polypharmacy among youths. This session will include presentations by James M. Swanson, M.D. and Joseph Biederman, M.D. regarding the effectiveness of the pediatric formulation of Modafinil in children and adolescents with ADHD. Kiki D. Chang, M.D. and Martha J. Little, M.D. will co-chair this session.

Tuesday, May 24, 2005 from 11:00-12:30 pm in the Pine Room, South Tower, Atrium Terrace Level, Omni Hotel.

PTSD and Anxiety

Dr. Andrea Bradford and Dr. Asher Simon will co-chair this Scientific and Clinical Reports session. The PRN's Josh Wilk, PhD will discuss the possible under-diagnosis and under-treatment of anxiety disorders in psychiatry. Rima Styra, M.D. talks about PTSD, depression and anger in patients recovered from SARS, and Friedhelm Lamprecht, M.D. will address the biological findings in PTSD.

Tuesday, May 24, 2005 from 11:00-12:30 pm in the Cottonwood Room, Street Level, North Tower, Omni Hotel.

Trends and Characteristics of Inpatient Treatment in the U.S.

Ira D. Glick, M.D. will chair this symposium with Dr. Steven S. Sharfstein serving as co-chair and discussant. Dr. Glick will also present an updated model for inpatient psychiatric care. Anita S. Everett, M.D. will discuss the role of public policy and inpatient psychiatric care. Wayne S. Fenton, M.D. will discuss crisis residential care for patients with serious mental illness, the outcomes and cost. Edward R. Shapiro, M.D. will provide information about a national referral center for treatment resistant patients, and Josh Wilk, Ph.D. will discuss the trends and characteristics of inpatient treatment in routine psychiatric practice in the US.

Tuesday, May 24, 2005 from 2:00-5:00 pm in Room B408, Level 4, Georgia World Congress Center.

Barriers to the Effective Treatment of Personality Disorders

Donna S. Bender, M.D. and Andrew E. Skodol II, M.D., will co-chair this symposium, with John M. Oldham, M.D. serving as discussant. Dr. Bender will also present information on utilization and barriers to treatment by patients with personality disorders. Dr. Skodol will discuss the recognition of personality disorders in mental health settings. William Narrow, M.D. will discuss the patterns and barriers to treatment of personality disorders in psychiatric practice. Drew Westen, Ph.D. will discuss barriers to effective research on treatment of personality disorders, and Glen Gabbard, M.D. will discuss stigma, countertransference and personality disorders.

Thursday, May 26, 2005 from 2:00-5:00 pm in Room B314, Level 3, Georgia World Congress Center.

Practice Research Network Members and Liaisons Breakfast Meeting

Members and liaisons will discuss current PRN research initiatives and plans for future studies. Please RSVP by calling 800-713-7123 or emailing Lisa Countis at lcountis@psych.org.

Monday, May 23, 2005 from 7:30 to 9:00 am in Room B411, Level 4 of the Georgia World Congress Center.



Treatment of First Episode Psychosis:

Initial Pilot is PRN's First Successful Longitudinal Clinical Study

The PRN collaborated with Mark Olfson, M.D., M.P.H., principal investigator on an NIMH-funded longitudinal pilot study of the management and outcomes of first use of antipsychotic medications for schizophrenia and other psychotic disorders. Now completed, the study involved surveying 200 psychiatrists and primary care physicians who followed the clinical course of treatment for "first episode" patients for six months. Seventy-one percent of the eligible physicians identified as prescribing an antipsychotic to a patient for the first time completed the baseline data collection instrument; 82% also completed the two-month clinical assessment; and 73% completed the six month clinical assessment.

Consistent with the published literature, the preliminary pilot data suggest that although the treating physicians perceive antipsychotic medications as effective for most patients, early treatment drop-out and problems with medication adherence are common. The most common primary clinical diagnoses were schizophrenia, schizophreniform, or schizoaffective disorder which collectively accounted for approximately half of the patients; approximately 40% of the patients were identified as having bipolar disorder, and fewer than 5% were diagnosed with major depression with psychotic features or other psychotic disorders. All of the patients were prescribed second generation antipsychotic medications and about half received concurrent treatment with antidepressants, about 40% received anxiolytics and nearly a third received mood stabilizers. Although at the two month clinical assessment antipsychotic drug therapy was perceived to be effective or very effective in nearly 70% of the cases, several patients were reported to have problems with medication adherence. Approximately one in ten patients had stopped taking antipsychotic medications altogether and about a quarter were having significant problems adhering to the prescribed antipsychotic regimen.

Continued pilot work is now being conducted to provide data for a revision to an NIMH grant application, *National Study of Treatment of First Episode Psychosis*. Overall aims of the study are to assess access to treatments, to determine whether and to what extent modifiable physician behaviors influence continuity of treatment in first episode psychosis, and to test whether the development of a strong therapeutic alliance and patient self-management skills extend continuity of treatment and improve clinical outcomes.



PRN Member Highlight *James E. Nininger, M.D.*

Dr. Nininger has been an active PRN member since it was first established in 1993 and served as the Area 2 PRN Liaison for nine years. Despite his many other activities and competing APA leadership responsibilities, including serving as Speaker of the APA Assembly this past year, Dr. Nininger has been a familiar and welcomed face at PRN meetings over the past decade. He has consistently provided helpful advice and constructive critical feedback on all of the major PRN research initiatives – with careful scrutiny to make sure study instruments would be valid and generate data of greatest relevance.

"Jim Nininger has been a major factor in the PRN's success. As a clinician he has provided much guidance to the development of the instruments and as an Association leader he has been central to the implementation efforts," notes John S. McIntyre, M.D., founding chair of the PRN's Steering Committee.

A fellow of the APA, Dr. Nininger has served in numerous professional, community leadership and volunteer capacities, including Chair of the Area 2 Committee on Aging, Assembly Liaison to the APA Committee on AIDS and the Committee on Family Violence and Sexual Abuse, and serving on the APA Task Force on Psychiatry and Nursing Homes. He has been a member of several Task Forces on the Homeless. In addition, he has served as the Area 2 liaison to the Practice Guidelines Steering Committee since its inception. Dr. Nininger is Clinical Associate Professor of Psychiatry at Cornell University Medical College and is board certified in geriatric psychiatry. He's also the proud father of three children.

Recently Published Findings from the PRN . . .


- Patterns and Quality of Treatment for Patients with Schizophrenia in Routine Psychiatric Practice. *Psychiatric Services* 2005; 56(3): 283-291.
- Access to Psychiatric Services for Patients with Different Types of Insurance and Health Plans. *Psychiatric Services* 2005; 56(4): 408-410.
- Access to Evidence-Based Psychopharmacologic and Psychosocial Treatments for Patients with Major Depressive Disorder. *FOCUS* 2005; 3(1): 43-50.
- Concomitant Pharmacotherapy Among Children and Adolescents Treated in Routine Psychiatric Practice. *Journal of Child and Adolescent Psychopharmacology* 2005; 15(1): 12-25.
- The Geriatric Psychiatry Workforce in 2002: Analysis from the 2002 National Survey of Psychiatric Practice. *American Journal of Geriatric Psychiatry* Accepted for publication 2005.
- Quality of Care Measures for the Treatment of Bipolar Disorder. *Psychiatric Quarterly*, 3rd quarter 2005.
- A Comparison of Patients and Treatment in Randomized Controlled Trials with Patients and Treatments in a Practice Research Network. *Social Psychiatry and Psychiatric Epidemiology* 2005; 40(1):27-35.

Factors Associated with Provision of Clinically-Suggested Psychotherapy to Patients of Psychiatrists

Psychotherapy has long been recognized as a key component of psychiatric care, with evidence of better outcomes for patients who receive both psychopharmacologic treatment and psychotherapy versus those with psychopharmacologic treatment alone (1,2). Despite the expanding evidence base for psychotherapies over the past decade, studies of the use of psychotherapy in psychiatric practice have found that use of evidence-based psychotherapy has declined in recent years (3). Concerns have been raised regarding access to psychotherapy as a result of changes in the financing and management of care.

Data from the PRN 1999 *Study of Psychiatric Patients and Treatments* found that over 65% of adult patients of psychiatrists received some form of psychotherapy from the physician or another provider in the last 30 days. However, over one-third of adult patients for whom psychotherapy was clinically-suggested as recommended by evidence-based treatment guidelines (i.e., the patient had a comorbid Axis II disorder, a treatment compliance problem, or any DSM-IV Axis IV psychosocial problem as rated by the psychiatrist) did not receive it, with over half of all patients with schizophrenia not receiving clinically-suggested therapy. As shown in Figure 1, patients whose care was subjected to utilization review, had Medicaid as the main source of payment, were work disabled, were diagnosed with schizophrenia, were over 65, or African-American were significantly less likely to receive clinically-suggested psychotherapy. Those patients who were seen in solo office practices, were self-pay or had private insurance, or had a diagnosis of depression were significantly more likely to receive clinically-suggested psychotherapy.

Figure 1. Percent of Patients Least Likely to Receive Clinically-Suggested Psychotherapy (N=1,393; p<.05)



1999 PRN Study of Psychiatric Patients and Treatments (SPPT)

The lack of psychotherapy provided to over a third of patients in which it is clinically-suggested could result in significantly poorer functioning and treatment outcomes for these patients, as well as diminished cost-effectiveness of care provided (e.g., patients who do not receive psychotherapy in conjunction with psychopharmacologic treatment may be less adherent to their medication regime and their overall treatment plan). These findings would be useful in informing health care financing policy and services delivery models to enhance provision of clinically-suggested, evidence-based psychotherapies.

References

1. Keller MB, McCullough JP, Klein DN, et al: A comparison of nefazadone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression; *N Engl J Med*; 342:1462-1470, 2000.
2. Lehman AF, Steinwachs, DM: Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. *Schizophrenia Bulletin* 24:1-10, 1998.
3. Olfson M, Marcus S, Pincus H: Trends in Office-Based Psychiatric Practice. *American Journal of Psychiatry* 156:451-457, 1999.

APF Barriers to Care

continued from page 2

by SAMHSA. For the third proposal, an NIMH grant application, *National Study of Treatment of First Episode Psychosis* (Mark Olfson, MD, MPH, Principal Investigator), we are undertaking further pilot study. Finally, APF funds are supporting a number of studies highlighting barriers to treatment for mental and addictive disorders using existing PRN databases, including those published studies listed in this newsletter (see page 3).

Future Directions for the PRN

Future directions now being explored for the PRN build on the strengths and success of past PRN efforts, while testing innovative new approaches and initiatives. The overall goal of these initiatives is to further expand the capacity of the network to generate practice-based data that will inform clinical practice and health care policies that will improve access and quality of care for patients.

PRN Study of Psychiatric Patients and Treatments (SPPT). Last implemented in 1999, the SPPT has provided a valuable database characterizing psychiatric patients and the treatments they receive. It has resulted in over 100 scientific communications, including papers on access to treatments, racial and ethnic differences in psychiatric diagnosis and treatment, and quality of psychopharmacologic and psychosocial treatments for the full range of mental and addictive disorders. Our plans envision the next *SPPT* to assess the impact of proposed changes in the financing and delivery of

Future Directions

continued from page 5

Medicaid and Medicare programs on treatment access and continuity. The study also will examine issues of particular relevance to the *APF Barriers to Care* grant, including assessing and quantifying delays and barriers to treatment.

Assessing the Impact of Medicare Part D on Medication Continuity for Medicaid/Medicare Dual Eligibles. As the Medicare Part D program is implemented in Fall 2005, the new prescription drug benefit management plans which will competitively bid to provide and manage prescription drug benefits for this population on a capitated basis may lead to significant disruptions in medication continuity. Currently medications for this population are provided under state Medicaid programs. PRN staff are collaborating with the *APA Division of Healthcare System and Financing* to field a study to document the effect of this policy change and any unintended adverse consequences that may occur as a result of medication switches or discontinuation.

Testing Electronic Health Records and Electronic Prescribing. The use of electronic health records and electronic prescribing is being encouraged through financial and other incentives by payors to increase efficiency and quality of care. As this initiative ramps up, identifying and testing administratively feasible and effective systems for psychiatry which also address security and confidentiality concerns, is increasingly important. Because these electronic platforms could provide a valuable clinical database for supporting PRN research initiatives, we will seek funding for pilot testing and demonstrations in the PRN.

Testing an Interactive Clinical Practice Assessment and Quality Improvement Module to Fulfill Future ABPN Recertification and Maintenance of Certification Requirements. In light of new APBN and CME requirements, we have been working with the *APA Division of Education* to develop an *Interactive Clinical Practice Assessment and Quality Improvement* module. This brief electronic clinical tool would systematically assess the extent to which clinicians' patients appear to be receiving treatment consistent with evidence-based practice guideline recommendations for most major mental and addictive disorders. Areas for potential changes in practice would be flagged for the clinician along with the evidence-based guideline recommendations and relevant clinical resources using audit and feedback methods which have been shown to be effective. The *APA Division of Education* has already developed a demonstration model. Since most traditional CME has not been shown to be effective in promoting best practices, there is significant interest in this effort by the ABMS and ABPN. Many specialty societies are working on this type of project for their members.

Enhancing Treatment for Individuals with Co-Occurring Disorders and Strengthening the Substance Abuse Treatment Capacity. Data from the PRN indicate that the majority of psychiatric patients with identified alcohol, nicotine and other substance use disorders have not received any substance use treatment from the treating psychiatrist or any other provider within the past 30 days. The PRN is working with the *APA Council on Addictions* and its members to strengthen the role that psychiatrists and other physicians can play in treating substance use disorders. With new psychopharmacologic, psychosocial and other treatment options for nicotine as well as alcohol and other substance dependencies, psychiatry's leadership in this area in specialty mental health and primary care settings is increasingly important.

We look forward to discussing these proposed initiatives at the upcoming *PRN Members and Liaisons Breakfast* meeting that will take place in Atlanta during the 2005 APA Annual Meeting (see page 3).

PRN Contact Information

PRN AREA LIAISONS

John S. McIntyre, M.D., Chair

Marvin Koss, M.D.

(Area 2, 315-464-5631)

Jorge A. Pereira-Ogan, M.D.

(Area 3, 302.654.6353)

Richard Balon, M.D.

(Area 4, 313.993.3416)

Martin J. Kommor, M.D.

(Area 5, 304.341.1500)

Albert C. Gaw, M.D.

(Area 6, 415.206.6337)

James E. Campbell, M.D.

(Area 7, 602.978.1844)

PRN STEERING

COMMITTEE MEMBERS

Diana Perkins, M.D.

Gail Barton, M.D., M.P.H.

Louis A. Moench, M.D.

Miriam Tasini, M.D.

Ronald Burd, M.D.

Ronnie Stangler, M.D.

APIRE PRN STAFF

Darrel A. Regier, M.D., M.P.H.
Executive Director, APIRE

Joyce C. West, Ph.D., M.P.P.
Director, PRN

William E. Narrow, M.D., M.P.H.
Farifteh F. Duffy, Ph.D.

Maritza Rubio-Stipec, Sc.D.

Josh Wilk, Ph.D.

Doanld S. Rae, M.S.

Rebecca Hall, B.S.

Lisa Countis

Tel: 800.713.7123

Fax: 703.907.1087

Email: apapr@psych.org

THE PRN ACKNOWLEDGES THE GENEROUS SUPPORT OF THE AMERICAN PSYCHIATRIC FOUNDATION, THE NATIONAL INSTITUTE OF MENTAL HEALTH, THE CENTER FOR MENTAL HEALTH SERVICES, THE CENTER FOR SUBSTANCE ABUSE TREATMENT, AND THE JOHN D. AND CATHERINE T. MACARTHUR FOUNDATION.